Literature DB >> 22926515

ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.

A P Rebocho1, R Marais.   

Abstract

The RAF proteins are cytosolic protein kinases that regulate cell responses to extracellular signals. There are three RAF proteins in cells, ARAF, BRAF and CRAF, and recent studies have shown that the formation of complexes by these different isoforms has an important role in their activation, particularly in response to RAF inhibitors. Here, we investigated the role of ARAF in cancer cell signaling and examined the role of ARAF in mediating paradoxical activation of the MAPK pathway in cells treated with RAF inhibitors. We show that two mutations that occur in ARAF in cancer inactivate the kinase. We also show that ARAF is not functionally redundant with CRAF and cannot substitute for CRAF downstream of RAS. We further show that ARAF binds to and is activated by BRAF and that ARAF also forms complexes with CRAF. Critically, ARAF seems to stabilize BRAF:CRAF complexes in cells treated with RAF inhibitors and thereby regulate cell signaling in a subtle manner to ensure signaling efficiency.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926515     DOI: 10.1038/onc.2012.330

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

Review 1.  No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

Authors:  Maria Romina Girotti; Grazia Saturno; Paul Lorigan; Richard Marais
Journal:  Mol Oncol       Date:  2014-08-15       Impact factor: 6.603

2.  Spatial regulation of ARAF controls the MST2-Hippo pathway.

Authors:  Jens Rauch; Walter Kolch
Journal:  Small GTPases       Date:  2017-03-10

Review 3.  BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Authors:  M E Cabanillas; A Patel; B P Danysh; R Dadu; S Kopetz; G Falchook
Journal:  Horm Cancer       Date:  2014-12-03       Impact factor: 3.869

4.  Analysis of K-Ras Interactions by Biotin Ligase Tagging.

Authors:  Christopher Ritchie; Andrew Mack; Logan Harper; Ayna Alfadhli; Philip J S Stork; Xiaolin Nan; Eric Barklis
Journal:  Cancer Genomics Proteomics       Date:  2017 Jul-Aug       Impact factor: 4.069

5.  ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1.

Authors:  Wenjing Su; Radha Mukherjee; Rona Yaeger; Jieun Son; Jianing Xu; Na Na; Neilawattie Merna Timaul; Jaclyn Hechtman; Viktoriya Paroder; Mika Lin; Marissa Mattar; Juan Qiu; Qing Chang; Huiyong Zhao; Jonathan Zhang; Megan Little; Yuta Adachi; Sae-Won Han; Barry S Taylor; Hiromichi Ebi; Omar Abdel-Wahab; Elisa de Stanchina; Charles M Rudin; Pasi A Jänne; Frank McCormick; Zhan Yao; Neal Rosen
Journal:  Mol Cell       Date:  2022-05-24       Impact factor: 19.328

6.  miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma.

Authors:  Lijoy K Mathew; Nicolas Skuli; Vera Mucaj; Samuel S Lee; Pascal O Zinn; Pratheesh Sathyan; Hongxia Z Imtiyaz; Zhongfa Zhang; Ramana V Davuluri; Shilpa Rao; Sriram Venneti; Priti Lal; Justin D Lathia; Jeremy N Rich; Brian Keith; Andy J Minn; M Celeste Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-24       Impact factor: 11.205

7.  The non-linearity of RAF-MEK signaling in dendritic cells.

Authors:  Kristina Riegel; Krishnaraj Rajalingam
Journal:  Cell Cycle       Date:  2020-08-04       Impact factor: 4.534

8.  Allosteric activation of functionally asymmetric RAF kinase dimers.

Authors:  Jiancheng Hu; Edward C Stites; Haiyang Yu; Elizabeth A Germino; Hiruy S Meharena; Philip J S Stork; Alexandr P Kornev; Susan S Taylor; Andrey S Shaw
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

9.  ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.

Authors:  Ivana Yen; Frances Shanahan; Jeeyun Lee; Yong Sang Hong; Sang Joon Shin; Amanda R Moore; Jawahar Sudhamsu; Matthew T Chang; Inhwan Bae; Darlene Dela Cruz; Thomas Hunsaker; Christiaan Klijn; Nicholas P D Liau; Eva Lin; Scott E Martin; Zora Modrusan; Robert Piskol; Ehud Segal; Avinashnarayan Venkatanarayan; Xin Ye; Jianping Yin; Liangxuan Zhang; Jin-Soo Kim; Hyeong-Seok Lim; Kyu-Pyo Kim; Yu Jung Kim; Hye Sook Han; Soo Jung Lee; Seung Tae Kim; Minkyu Jung; Yoon-Hee Hong; Young Su Noh; Munjeong Choi; Oakpil Han; Malgorzata Nowicka; Shrividhya Srinivasan; Yibing Yan; Tae Won Kim; Shiva Malek
Journal:  Nature       Date:  2021-05-05       Impact factor: 49.962

Review 10.  Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets.

Authors:  Giuseppe Palmieri; MariaNeve Ombra; Maria Colombino; Milena Casula; MariaCristina Sini; Antonella Manca; Panagiotis Paliogiannis; Paolo Antonio Ascierto; Antonio Cossu
Journal:  Front Oncol       Date:  2015-08-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.